3Q EARNINGS: Teva's Copaxone sales surprise boosts stock
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries surprised investors with a 5% increase in Copaxone sales during the third quarter, but stock buyers' confidence also was boosted by the company's improved profitability and a decision to increase its share buyback plan from $1.7bn to $3bn.